Hudson Bay Capital Management LP Purchases 55,689 Shares of Viridian Therapeutics, Inc. $VRDN

Hudson Bay Capital Management LP boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 46.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 175,251 shares of the company’s stock after purchasing an additional 55,689 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Viridian Therapeutics were worth $3,782,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in VRDN. US Bancorp DE grew its position in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after acquiring an additional 876 shares during the period. Sei Investments Co. lifted its position in Viridian Therapeutics by 10.0% during the 3rd quarter. Sei Investments Co. now owns 11,556 shares of the company’s stock valued at $249,000 after acquiring an additional 1,046 shares during the period. Knights of Columbus Asset Advisors LLC boosted its stake in Viridian Therapeutics by 2.4% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company’s stock worth $1,282,000 after acquiring an additional 1,386 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Viridian Therapeutics by 1.3% during the second quarter. Swiss National Bank now owns 108,900 shares of the company’s stock worth $1,522,000 after acquiring an additional 1,400 shares in the last quarter.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $26.98 on Friday. The firm’s 50 day moving average price is $30.24 and its 200-day moving average price is $27.54. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $2.76 billion, a PE ratio of -8.20 and a beta of 1.00. Viridian Therapeutics, Inc. has a twelve month low of $9.90 and a twelve month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $15.75 million. Equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Insider Activity at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.58% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Evercore reiterated an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Wells Fargo & Company lifted their price objective on Viridian Therapeutics from $26.00 to $29.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Royal Bank Of Canada reduced their price target on Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 27th. UBS Group initiated coverage on shares of Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, William Blair started coverage on shares of Viridian Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.21.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.